Raw Materials powder Nafamostat mesylate

CAS:82956-11-4

MF:C21H25N5O8S2

MW:539.58

EINECS:692-168-2

Specification​: 99% min Nafamostat mesylate powder

Sample:Nafamostat mesylate powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Nafamostat mesylate powder Usage and Synthesis.

Naproxat mesylate for injection is a Western medicine, mainly suitable for:

Prevent blood clotting by perfusion during cardiopulmonary bypass (hemodialysis and plasma storage).

Treatment of acute pancreatitis, acute worsening chronic pancreatitis, postoperative acute pancreatitis, acute pancreatitis after pancreatic angiography and acute traumatic pancreatitis.

Treatment of disseminated intravascular coagulation (DIC).

Namorestat mesylate is a synthetic protease inhibitor, which can prolong coagulation time, inhibit platelet agglutination and complement hemolysis by inhibiting coagulation fibrinolysis system, kallikrein · kinin system and complement system.

Uses of Nafamostat mesylate.

Protease inhibitors. It can strongly inhibit trypsin-like serine proteases such as membrane protease, skin kinase releasing enzyme, blood fibrinolytic enzyme, fibrinase and classical pathways of the complement system Clr-, Cls-, and phospholipase A2, trypsin binding with α-macroglobulin in vitro, as well as free trypsin. It is used to improve acute pancreatitis, acute deterioration of chronic pancreatitis, acute pancreatitis after surgery, acute pancreatitis after pancreatic angiography and traumatic pancreatitis.

In vitro study of Nafamostat mesylate.

Nafamostat mesylate significantly inhibits platelet beta-platelet globulin (release at 60 and 120 minutes). Nafamostat mesylate (NM) significantly prevents the release of any neutrophil elastase; At 120 min, the plasma protease-α1-antitrypsin complex was 0.16 mg/ml in the NM group and 1.24 mg/ml in the control group. Nafamostat mesylate completely inhibits C1 inhibitors from forming complexes with kalokinase and FXIIa mesylate.

Nafamostat mesylate inhibits several proteases and may be involved in the pathophysiology of diffuse intravascular coagulation (DIC). Nafamostat mesylate inhibits the activity of exogenous pathways (TF-F.ViiIA-XA factor production) in a concentration-dependent manner with an IC50 of 0.1μM. Nafamostat mesylate concentration dependent suppression of the initial phase transient component of the biphasic ASIC3 current with an IC50 value of approximately 2.5mM.

Product method of Bulk Nafamostat mesylate.